Nichi-Iko Seeks To Acquire Teikoku Medix To Be Largest Japanese Generic
This article was originally published in PharmAsia News
Nichi-Iko Pharmaceutical plans to acquire Teikoku Medix, also of Japan, in a bid to become the largest maker of generic drugs in the country. The Nichi-Iko plan is to make the move as early as this summer and turn the Teikoku unit into a wholly owned subsidiary. The value of Teikoku Medix stock, owned by Teikoku Seiyaku, is estimated at about $70 million. The planned merger would combine sales worth $424 million, more than any other generic in Japan. (Click here for more - a subscription may be required
You may also be interested in...
Chobani introduces Chobani Probiotic, its first functional probiotics beverage to support digestive and immune health; Danone North America extends its Danimals children’s yogurt line with products to support immune system; and Plexus Worldwide and Sofar Americas roll out children’s probiotics.
Report quantifies social media posts describing adverse events involving the Essure contraceptive device, which was pulled from the market amid safety concerns.